Intravitreal Injections of Ziv-aflibercept for Macular Diseases: Diabetic Macular Edema, Wet AMD and Macular Edema Secondary to Vein Occlusons

Trial Profile

Intravitreal Injections of Ziv-aflibercept for Macular Diseases: Diabetic Macular Edema, Wet AMD and Macular Edema Secondary to Vein Occlusons

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Diabetic macular oedema; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 30 Sep 2016 Planned End Date changed from 1 Sep 2017 to 1 Sep 2016.
    • 04 Jul 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top